Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion

Douglas L. Riegert-Johnson, John A. Godfrey, Jeffrey L. Myers, Rolf D. Hubmayr, William J. Sandborn, Edward Vincent Loftus, Jr

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Infliximab, a chimeric human/murine monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor alpha, is an effective therapy for Crohn's disease (CD) and rheumatoid arthritis refractory to standard medical treatment. We report a case of adult respiratory distress syndrome associated with infliximab therapy. A 33-year-old white male presented with an exacerbation of CD and was treated with his second infliximab infusion (15 months following the first infusion). Within 7 days he developed arthralgias, myalgias, and fever, followed by respiratory failure. He required intubation and mechanical ventilation. Open lung biopsy demonstrated eosinophilic pneumonia. Human antichimeric antibodies were present at high concentrations. An extensive investigation for infectious etiologies was negative. The patient was treated with intravenous corticosteroids, and fully recovered after a prolonged hospitalization. We review the infectious and immunologic complications of infliximab.

Original languageEnglish (US)
Pages (from-to)186-191
Number of pages6
JournalInflammatory Bowel Diseases
Volume8
Issue number3
StatePublished - 2002

Fingerprint

Adult Respiratory Distress Syndrome
Delayed Hypersensitivity
Crohn Disease
Pulmonary Eosinophilia
Myalgia
Arthralgia
Artificial Respiration
Intubation
Respiratory Insufficiency
Rheumatoid Arthritis
Adrenal Cortex Hormones
Hospitalization
Fever
Therapeutics
Tumor Necrosis Factor-alpha
Monoclonal Antibodies
Cytokines
Biopsy
Lung
Infliximab

Keywords

  • Acute respiratory distress syndrome
  • Adverse drug reaction
  • Crohn's disease
  • Eosinophilic pneumonia
  • Infliximab
  • Tumor necrosis factor-alpha

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Riegert-Johnson, D. L., Godfrey, J. A., Myers, J. L., Hubmayr, R. D., Sandborn, W. J., & Loftus, Jr, E. V. (2002). Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflammatory Bowel Diseases, 8(3), 186-191.

Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. / Riegert-Johnson, Douglas L.; Godfrey, John A.; Myers, Jeffrey L.; Hubmayr, Rolf D.; Sandborn, William J.; Loftus, Jr, Edward Vincent.

In: Inflammatory Bowel Diseases, Vol. 8, No. 3, 2002, p. 186-191.

Research output: Contribution to journalArticle

Riegert-Johnson, DL, Godfrey, JA, Myers, JL, Hubmayr, RD, Sandborn, WJ & Loftus, Jr, EV 2002, 'Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion', Inflammatory Bowel Diseases, vol. 8, no. 3, pp. 186-191.
Riegert-Johnson, Douglas L. ; Godfrey, John A. ; Myers, Jeffrey L. ; Hubmayr, Rolf D. ; Sandborn, William J. ; Loftus, Jr, Edward Vincent. / Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. In: Inflammatory Bowel Diseases. 2002 ; Vol. 8, No. 3. pp. 186-191.
@article{6fd8f521deeb4c3fa71a697f682a8ced,
title = "Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion",
abstract = "Infliximab, a chimeric human/murine monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor alpha, is an effective therapy for Crohn's disease (CD) and rheumatoid arthritis refractory to standard medical treatment. We report a case of adult respiratory distress syndrome associated with infliximab therapy. A 33-year-old white male presented with an exacerbation of CD and was treated with his second infliximab infusion (15 months following the first infusion). Within 7 days he developed arthralgias, myalgias, and fever, followed by respiratory failure. He required intubation and mechanical ventilation. Open lung biopsy demonstrated eosinophilic pneumonia. Human antichimeric antibodies were present at high concentrations. An extensive investigation for infectious etiologies was negative. The patient was treated with intravenous corticosteroids, and fully recovered after a prolonged hospitalization. We review the infectious and immunologic complications of infliximab.",
keywords = "Acute respiratory distress syndrome, Adverse drug reaction, Crohn's disease, Eosinophilic pneumonia, Infliximab, Tumor necrosis factor-alpha",
author = "Riegert-Johnson, {Douglas L.} and Godfrey, {John A.} and Myers, {Jeffrey L.} and Hubmayr, {Rolf D.} and Sandborn, {William J.} and {Loftus, Jr}, {Edward Vincent}",
year = "2002",
language = "English (US)",
volume = "8",
pages = "186--191",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion

AU - Riegert-Johnson, Douglas L.

AU - Godfrey, John A.

AU - Myers, Jeffrey L.

AU - Hubmayr, Rolf D.

AU - Sandborn, William J.

AU - Loftus, Jr, Edward Vincent

PY - 2002

Y1 - 2002

N2 - Infliximab, a chimeric human/murine monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor alpha, is an effective therapy for Crohn's disease (CD) and rheumatoid arthritis refractory to standard medical treatment. We report a case of adult respiratory distress syndrome associated with infliximab therapy. A 33-year-old white male presented with an exacerbation of CD and was treated with his second infliximab infusion (15 months following the first infusion). Within 7 days he developed arthralgias, myalgias, and fever, followed by respiratory failure. He required intubation and mechanical ventilation. Open lung biopsy demonstrated eosinophilic pneumonia. Human antichimeric antibodies were present at high concentrations. An extensive investigation for infectious etiologies was negative. The patient was treated with intravenous corticosteroids, and fully recovered after a prolonged hospitalization. We review the infectious and immunologic complications of infliximab.

AB - Infliximab, a chimeric human/murine monoclonal antibody directed against the proinflammatory cytokine tumor necrosis factor alpha, is an effective therapy for Crohn's disease (CD) and rheumatoid arthritis refractory to standard medical treatment. We report a case of adult respiratory distress syndrome associated with infliximab therapy. A 33-year-old white male presented with an exacerbation of CD and was treated with his second infliximab infusion (15 months following the first infusion). Within 7 days he developed arthralgias, myalgias, and fever, followed by respiratory failure. He required intubation and mechanical ventilation. Open lung biopsy demonstrated eosinophilic pneumonia. Human antichimeric antibodies were present at high concentrations. An extensive investigation for infectious etiologies was negative. The patient was treated with intravenous corticosteroids, and fully recovered after a prolonged hospitalization. We review the infectious and immunologic complications of infliximab.

KW - Acute respiratory distress syndrome

KW - Adverse drug reaction

KW - Crohn's disease

KW - Eosinophilic pneumonia

KW - Infliximab

KW - Tumor necrosis factor-alpha

UR - http://www.scopus.com/inward/record.url?scp=0036106469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036106469&partnerID=8YFLogxK

M3 - Article

C2 - 11979139

AN - SCOPUS:0036106469

VL - 8

SP - 186

EP - 191

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 3

ER -